ImmuPharma (LON:IMM) Trading Up 28.8% - Should You Buy?

Key Points

• ImmuPharma's stock surged by 28.8% during trading, reaching a high of GBX 15.23 ($0.21) before settling at GBX 13.98 ($0.19).
• The company's market cap stands at £69.86 million, but it reported a negative PE ratio of -1,570.67 and a significant negative return on equity of 131.41%.
• ImmuPharma is focused on developing peptide-based therapeutics for autoimmune diseases, with its lead program, Lupuzor™, targeting lupus treatment.

ImmuPharma plc (LON:IMM - Get Free Report) was up 28.8% during trading on Friday . The stock traded as high as GBX 15.23 ($0.21) and last traded at GBX 13.98 ($0.19). Approximately 44,749,293 shares traded hands during trading, an increase of 451% from the average daily volume of 8,119,573 shares. The stock had previously closed at GBX 10.85 ($0.15).

ImmuPharma Price Performance

The company has a market cap of £69.86 million, a PE ratio of -1,570.67 and a beta of 1.53. The company has a fifty day moving average price of GBX 2.88 and a 200 day moving average price of GBX 2.86.

ImmuPharma (LON:IMM - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. As a group, sell-side analysts predict that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.